The Implantable Miniature Telescope for Macular Degeneration

Scheie Eye Institute, University of Pennsylvania
Wednesday, November 30, 2016
Illustration of the implantable miniature telescope
VisionCare Ophthalmic Technologies, Inc.

Some patients with age-related macular degeneration (AMD) lose their central vision in both eyes. This makes it difficult to read, recognize faces, or watch television. Fortunately, the more peripheral retinal beyond the centrally-located macula is not usually affected. The implantable miniature telescope (IMT) takes advantage of this fact by enlarging objects in the center of the visual field so they can be seen by the intact parts of the retina around the macula.

The IMT has been tested in clinical trials and is approved by the FDA for patients with corrected vision of 20/160 – 20/800) that is caused by bilateral end-stage AMD. Patients with active wet AMD are not eligible. Patients must also achieve at least a 5-letter improvement on the visual acuity chart using a trial external telescope. This trial is an important predictor of the benefit from an IMT and can be used to simulate vision after telescope implantation. They must also have their natural lens in place at the time of IMT implantation; that is, no prior cataract surgery in that eye.

In January of 2017, VisionCare Ophthalmic Technologies™ announced approval by the FDA to initiate a new clinical trial to investigate the safety and efficacy of the telescopic implant in post-cataract surgery patients.

Illustration of the implantable miniature telescope
VisionCare Ophthalmic Technologies, Inc.

The IMT is implanted immediately after removal of the natural lens. Removal of the natural lens and implantation of a plastic lens is routine in standard cataract surgery.  Implantation of an IMT uses related techniques, and an IMT is implanted instead of the standard plastic intraocular lens (IOL). The IMT is about the size of a pea, and sits in the eye where the natural lens used to reside. Since the IMT is larger than an IOL, the incision required to insert it is larger. Complications of the surgery are infrequent, and include inflammation. An approximately 25% reduction in the number of cells lining the inside of the cornea commonly occurs, so the surgery is riskier for patients who start out with low numbers of corneal endothelial cells. These cells are needed to keep the cornea clear.

Two models of IMT are available: one with 2.2-times magnification and the other with 2.7-times magnification. This higher magnification version provides better visual acuity (by about a line on the eye chart), but slightly smaller visual field (20 versus 24 degrees). In the clinical trial, patients with the higher magnification telescope gained, on average, 3.6 lines on the eye chart, which is similar to improving from 20/160 to 20/80, or 20/200 to 20/100. According to a questionnaire, this resulted in a significant improvement in quality of life.

IMTs cause a decrease in depth perception, but this can improve with learning and experience over time. It is important to work with a low vision specialist and occupational therapist before and after surgery to determine whether the surgery is suitable for each person and to teach techniques for using the device. Generally, patients who are motivated to use their remaining vision benefit the most. These are patients who are already using low vision aids to sign their own checks and read large print. After implantation of an IMT, patients must practice looking at moving objects while sitting still, or looking at stationary objects while walking. It takes time and patience to get used to seeing magnified objects in the IMT-implanted eye, which now has tunnel vision, and using the other eye for peripheral vision. This has been compared to using monovision contact lenses; one to see distance and one for near.

The best results will be obtained from centers where surgeons have experience with the specialized implantation procedure. These centers must also have affiliated low vision optometrists and occupational therapists, both of whom are experienced with IMT training and are available both pre- and post-operatively.

The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.

These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.

Some of the content may be adapted from other sources, which will be clearly identified within the article.

More Like This

  • Illustration depicting medical imaging for macular degeneration

    Retinal Imaging for Diagnosing and Treating AMD

    The past decade has witnessed a revolution in retinal imaging providing detailed views of retinal changes in people who have age-related macular degeneration (AMD). Learn about the various forms of retinal imaging and how they help eye doctors diagnose and treat AMD

    Wednesday, October 11, 2017
  • Graphic of a strand of DNA.

    Update on Genetics and Age-Related Macular Degeneration

    Age-related macular degeneration (AMD) is caused by a number of genetic and environmental factors. People with an affected parent have approximately twice the risk of getting the disease than someone whose parents do not have AMD. Learn about the genes that increase the risk of AMD, and whether genetic testing is recommended.

    Thursday, September 28, 2017
  • Researcher using a pipette

    The Immune System and Macular Degeneration

    There is strong evidence that inflammation plays a role in the development of age-related macular degeneration (AMD). Learn why our immune system and inflammation contribute to AMD and how exciting research may lead to new, promising treatments.

    Thursday, September 28, 2017

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Keep me imformed about: *
Please select at least one.
You must select at least one disease category.
Please enter your first name.
Please enter your last name.